Trial Profile
Phase 2 Study of Epacadostat, Pembrolizumab, and CRS-207, With or Without Cyclophosphamide and GVAX Pancreas Vaccine in Patients With Metastatic Pancreas Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs CRS 207 (Primary) ; Cyclophosphamide (Primary) ; Epacadostat (Primary) ; Pembrolizumab (Primary) ; Tumour cell vaccine-GVAX (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 03 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 03 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.